Pembrolizumab, Dabrafenib, and Trametinib Improves Outcomes in BRAF-Mutant Melanoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
KEYNOTE-022 Part 3: A Randomized, Double-Blind, Phase 2 Study of Pembrolizumab, Dabrafenib, and Trametinib in BRAF-Mutant Melanoma
J Immunother Cancer 2020 Dec 01;8(2)e001806, PF Ferrucci, AM Di Giacomo, M Del Vecchio, V Atkinson, H Schmidt, J Schachter, P Queirolo, GV Long, R Stephens, IM Svane, M Lotem, M Abu-Amna, E Gasal, R Ghori, SJ Diede, ES Croydon, A Ribas, PA AsciertoFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.